Kuros Biosciences increases 2026 annual guidance, The company reports 40% year-over-year increase in sales in the first nine months of 2026

Kuros Biosciences increases 2026 annual guidance
The company reports 40% year-over-year increase in sales in the first nine months of 2026

Schlieren (Zurich), Switzerland, October 15, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial performance for the first nine months of 2026.

Financial Highlights

  • Total Medical Device sales increased 40% to USD 141.8 million (9M 2025: USD 101.1 million)
  • Total Group EBITDA increased 81% to USD 13.5 million (9M 2025: USD 7.4 million)
  • The Group adjusted EBITDA* increased 68% to USD 20.6 million, equaling a margin of 14.5% (9M 2025: USD 12.2 million or 12.1%)
  • Cash position ahead of plan at USD 19.6 million, up from USD 9.7 million as of June 30, 2026

Operational & Clinical Highlights

  • Made in the U.S. and the Netherlands – Kuros’ new Alpharetta, Georgia facility began commercial production of MagnetOs bone graft in October 2026. Together with its Bilthoven, Netherlands site, this gives Kuros dual-site manufacturing, including production in its largest market, to support capacity and supply-chain resilience
  • Level I trials pass key thresholds – PROOF reached 97% enrollment and PRECISE surpassed its halfway mark at 55%, advancing both posterolateral fusion studies. ASTRA advanced to 18% in hindfoot and ankle fusion, extending prospective evidence across spine and extremities

Outlook

  • Reflecting the continued strength of the business, the Group raises its full-year guidance and now expects sales growth of 36% to 40% and an adjusted EBITDA margin of more than 14.5%

Chris Fair, Chief Executive Officer of Kuros Biosciences, said “Our strong performance through the first nine months of 2026 reflects continued revenue growth, record adjusted EBITDA, increasing profitability and a cash position ahead of plan. I am particularly proud that we have activated our second production facility in Alpharetta, Georgia, on time and on budget. We are encouraged with the pace of enrollment in our three prospective Level I clinical trials across spine and extremities. We are pleased to raise our full-year 2026 guidance for revenue growth and adjusted EBITDA, even after these substantial investments.”

back